2026-09-11T15:16:17-05:00 2025-12-31 331374517 PKF O'CONNOR DAVIES ADVISORY LLC 500 MAMARONECK AVENUE SUITE 301 HARRISON NY 105281633 990 2025-01-01 133806788 THE OVARIAN CANCER RESEARCH FUND INC OVAR 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 AUDRA L MORAN PRESIDENT & CEO 2122681002 2026-09-11 1 MELISSA MODELSON P01603524 9143818900 2026-09-10 2025 OVARIAN CANCER RESEARCH ALLIANCE AUDRA L MORAN 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 25301177 0 X WWW.OCRAHOPE.ORG X 1994 NY OVARIAN CANCER RESEARCH ALLIANCE IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. 18 18 29 1937 0 0 8538194 17855600 301023 0 1219860 1754552 -11079 -77316 10047998 19532836 6428064 8681352 0 0 2887953 3741701 0 0 1954779 4240499 4915016 13556516 17338069 -3508518 2194767 38070603 42551929 14914782 15499304 23155821 27052625 X OVARIAN CANCER RESEARCH ALLIANCE (OCRA) IS COMMITTED TO PREVENTING, DEVELOPING BETTER TREATMENTS FOR AND ULTIMATELY CURING OVARIAN AND RELATED GYNECOLOGIC CANCERS THROUGH INNOVATIVE RESEARCH, RAISING AWARENESS AND ENSURING THE BEST CARE POSSIBLE THROUGH ADVOCACY AND SUPPORT FOR PATIENTS AND FAMILIES. 0 0 10447492 8681352 0 OVARIAN CANCER RESEARCH ALLIANCE WAS FOUNDED IN 1994 (AS THE OVARIAN CANCER RESEARCH FUND, INC.) AND IS A FULL-SPECTRUM ORGANIZATION FUNDING MEDICAL RESEARCH, ADVOCATING ON BEHALF OF PATIENTS AND PROVIDING SUPPORT AND RESOURCES TO PATIENTS AND THEIR FAMILIES.OVARIAN CANCER IS THE DEADLIEST OF ALL GYNECOLOGIC CANCERS AND RANKS FIFTH AS THE CAUSE OF CANCER DEATH IN WOMEN. IN 2025, THERE WERE 20,890 NEW CASES OF OVARIAN CANCER AND 12,730 DEATHS FROM THE DISEASE IN THE UNITED STATES. THE ACCOMPLISHMENTS OF OCRA'S PROGRAMS REFLECT OUR COMMITMENT TO THE OVARIAN AND GYNECOLOGIC CANCER COMMUNITIES. SINCE 1998, OCRA HAS AWARDED 457 GRANTS FOR OVARIAN AND RELATED CANCER RESEARCH TO PHYSICIANS AND SCIENTISTS AT 103 LEADING MEDICAL CENTERS, WHICH IS AN INVESTMENT TOTALING OVER $137 MILLION. THANKS TO THE GENEROSITY OF OUR DONORS, OUR INVESTIGATORS ARE WORKING ON MANY FRONTS TO DEFEAT OVARIAN CANCER. BY DEVELOPING INNOVATIVE STRATEGIES FOR EARLY DETECTION AND EXPLORING THE GENETICS THAT INCREASE RISK FOR OVARIAN CANCER, WE HOPE TO SAVE WOMEN'S LIVES BY FINDING THE CANCER EARLY OR STOPPING IT BEFORE IT EVEN STARTS. RESEARCHERS ARE GAINING INSIGHTS INTO THE MANY TYPES OF OVARIAN AND RELATED CANCERS TO DETERMINE THE ORIGINS, WHICH MAY LEAD TO MORE EFFECTIVE TESTING AND EFFECTIVE IMMUNOTHERAPY TREATMENT OPTIONS. FURTHERMORE, THEY ARE IDENTIFYING NEW AND BETTER TREATMENTS TO IMPROVE OVERALL SURVIVAL, PREVENT DRUG RESISTANCE, MINIMIZE SIDE EFFECTS, PREVENTING RECURRENCE AND METASTASIS AND ENHANCE PATIENTS' QUALITY OF LIFE. IN ADDITION TO OCRA'S ESTABLISHED RESEACH GRANT PROGRAM, OCRA ALSO CONTINUED THE HEALTH EQUITY RESEARCH GRANTS BEGUN IN 2023. THESE GRANTS FOCUS ON IMPROVING HEALTH EQUITY IN THE GYNECOLOGIC CANCER SPACE. AS PART OF OUR GLOBAL GYNECOLOGIC CANCER CONSORTIUM, MADE UP OF PARTNERS FROM THE UK, AUSTRALIA AND CANADA, OCRA LAUNCHED A NEW AI GRANT IN 2025. THE FIRST GRANT WAS AWARDED IN 2025 WITH A START DATE OF 2026. AND WITH THE RIVKIN CENTER JOINING OCRA IN 2025, THE FORMER RIVKIN PILOT GRANTS WERE ADDED, AS WELL. ACCOMPLISHMENTS ACHIEVED AS A RESULT OF OCRA GRANTS INCLUDE:IDENTIFIED A MOLECULE THAT COULD BE KEY TO IMPROVING IMMUNE RESPONSE AGAINST OVARIAN CANCER; SOUGHT TO UNDERSTAND WHY CERTAIN OVARIAN CANCER CELLS RESIST OLAPARIB TREATMENT, AND DISCOVERED THAT INTRODUCING A SECOND DRUG (MIFEPRISTONE) WHILE TARGETING CERTAIN CELLS (POLYPLOID GIANT CANCER CELLS) MAY OFFER A SOLUTION; IDENTIFIED A PREVIOUSLY UNKNOWN CHEMORESISTANT PATHWAY IN HGSC WHICH LED TO WORKING ON A NEW THERAPY TO OVERCOME THIS; SHED NEW LIGHT ON HOW THE MOST COMMON SUBTYPE OF OVARIAN CANCER DEVELOPS AND METASTASIZES, BY IDENTIFYING A KEY MOLECULE THAT ALLOWS MALIGNANCIES IN THE FALLOPIAN TUBE TO MIGRATE TO THE OVARIES AND CONTINUE TO GROW; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; SHOWED THAT RUCAPARIB EXTENDS PROGRESSION FREE SURVIVAL IN OVARIAN CANCER; DISCOVERED THAT 18% OF OVARIAN CANCER CASES INVOLVE INHERITED MUTATIONS; PINPOINTED TWO GENES THAT TRIGGER OVARIAN CANCER; DEMONSTRATED HOW GENE THERAPY MAY HELP PATIENTS WITH RECURRENT DISEASE; DISCOVERED THAT ANALYZING DATA FROM PAP SMEARS COULD HELP DETECT ENDOMETRIAL AND OVARIAN CANCER; ESTABLISHED THERE IS NO LINK BETWEEN OBESITY AND RISK FOR THE MOST COMMON TYPE OF OVARIAN CANCER; SHOWN THAT FGFR4 IS A PROGNOSTIC MARKER AND THERAPEUTIC TARGET FOR OVARIAN CANCER; DEFINED SIMILARITIES BETWEEN SOME ENDOMETRIAL, BREAST AND OVARIAN CANCERS; EXPLAINED HOW AN EXPERIMENTAL DRUG MAY BE HELPFUL IN FIGHTING PLATINUM-RESISTANT OVARIAN CANCER; IDENTIFIED BIOMARKERS THAT CAN BE USED TO MONITOR THE DEVELOPMENT OF PLATINUM RESISTANCE THERAPIES; IDENTIFIED NOVEL BIOMARKERS OF HGSOC AND SPECIFIC DRUG TARGETS; TARGETED MDM2 DEGRADATION AS A NOVEL TREATMENT FOR OVARIAN CANCER; USED MACHINE LEARNING TO BRIDGE THE GAP BETWEEN DISPARATE DATA SETS SPECIFICALLY IN PATIENTS WITH HGSOC; DOSED THE FIRST PATIENTS IN THE CLINICAL TRIAL "IMMUNOTHERAPY PLATFORM STUDY IN PLATINUM RESISTANT HIGH GRADE SEROUS OVARIAN CANCER (IPROC)" (NCT04918186); FOUND KEY PROTEINS IN HGSOC CANCER CELLS WHICH RESULTED IN COMBINED TREATMENT OPTIONS WHICH RESULTED IN SMALLER TUMORS AND LONGER SURVIVAL; SHOWED HOW SURGICAL REMOVAL OF FALLOPIAN TUBES MAY REDUCE OVARIAN CANCER RISK; UNCOVERED SEVERAL MECHANISMS OF IMMUNE ESCAPE TO HELP EXPLAIN SOME OVARIAN CANCERS' RESISTANCE TO IMMUNOTHERAPY; FOUND A DECREASE IN OVARIAN CARCINOMA INCIDENCE AFTER SALPINGECTOMY FOR TREATING ECTOPIC PREGNANCY; SHOWED PARP1 IS INVOLVED IN REPAIR OF TELOMERES, AND THAT IMPAIRING THIS PROCESS CAN LEAD TO TELOMERE SHORTENING AND GENOMIC INSTABILITY THAT CAN CAUSE CANCER; DEVELOPED A PROOF-OF-CONCEPT STUDY TO SHOW HOW THREE-DIMENSIONAL MODELING CAN SHOW HOW CANCER CELLS AND CAR-T INTERACT WHICH WILL HOPEFULLY LEAD TO BETTER TREATMENTS IN PATIENTS WITH HGSOC SOLID TUMORS; DISCOVERED THAT AGGRESSIVE OVARIAN CANCERS OFTEN SHOW SUDDEN LARGE-SCALE DNA DAMAGE, POINTING TO DISTINCT ORIGINS AND DETECTION STRATEGIES; AND IDENTIFIED THAT LOSS OF A GENE CALLED SMARCA4 MAKES OVARIAN CANCER CELLS MORE VISIBLE TO THE IMMUNE SYSTEM, BOOSTING IMMUNE ATTACK AND SUGGESTING A NEW STRATEGY TO IMPROVE IMMUNOTHERAPY.IN 2025 ALONE, OCRA RESEARCHERS: DEVELOPED A PIONEERING AI TOOL TO BETTER PREDICT TREATMENT RESPONSE, A STEP TOWARD EARLIER PERSONALIZED TREATMENT PLANS; SYSTEMATICALLY TESTED EXISTING THERAPIES TO FIND AN EFFECTIVE DRUG COMBINATION THAT SHOWS PROMISE; UNCOVERED KEY DIFFERENCES IN IMMUNE ENVIRONMENTS BETWEEN PRIMARY TUMORS AND METASTASES THAT MAY EXPLAIN WHY HIGH-GRADE SEROUS OVARIAN CARCINOMA OFTEN SUPPRESSES THE IMMUNE SYSTEM; FOUND THAT MUCINOUS OVARIAN CANCERS WITH KEY GENE CHANGES WERE ASSOCIATED WITH WORSE SURVIVAL EVEN AT EARLY STAGES, SUGGESTING GENETIC TESTING AT DIAGNOSIS MAY HELP GUIDE CARE AND PREDICT OUTCOMES; DISCOVERED THAT BLOCKING A KEY NUTRIENT WHILE ALSO USING IMMUNOTHERAPY COULD OFFER A PROMISING NEW TREATMENT STRATEGY FOR AROUND HALF OF OVARIAN CLEAR CELL CANCERS; FOUND THAT AMONG PEOPLE DIAGNOSED WITH AN EARLY OVARIAN CANCER PRECURSOR, OLDER PATIENTS AND BLACK PATIENTS FACE WORSE SURVIVAL, UNDERSCORING THE URGENT NEED FOR MORE TAILORED CARE AND TREATMENT STRATEGIES; FOUND THAT PROBIOTIC SUPPLEMENTS MAY HELP GYNECOLOGIC CANCER PATIENTS REDUCE RADIATION-RELATED GUT SIDE EFFECTS; FOUND THAT A SPECIFIC DNA-REPAIR PROTEIN HELPS CANCER CELLS GROW BY SWITCHING ON A GROWTH PATHWAY, HINTING AT A POTENTIAL TREATMENT TARGET TO MAKE TUMORS MORE TREATABLE WHILE SPARING HEALTHY CELLS; FOUND THAT ENGINEERED IMMUNE CELLS WORKED MUCH BETTER IN COMBINATION WITH THREE IMMUNOTHERAPIES, ALLOWING THE IMMUNE CELLS TO STAY ACTIVE LONGER AND KILL OVARIAN CANCER IN MICE MORE EFFECTIVELY; SHOWED THAT OVARIAN CANCER RECURRENCE IS DRIVEN BY A SMALL NUMBER OF PRE-EXISTING, TREATMENT-RESISTANT CANCER CELL CLONES WHICH ARE DETECTABLE THROUGH A NEW BLOOD TEST THAT MAY PAVE THE WAY TO PREVENTING RECURRENCE; FOUND THAT SPECIALLY ENGINEERED T CELLS THAT SECRETE "BITE" MOLECULES, WHEN COMBINED WITH OTHER IMMUNOTHERAPIES, CAN TRIGGER STRONG AND LASTING ANTI-TUMOR IMMUNE RESPONSES AGAINST OVARIAN CANCER IN MICE; FOUND A WAY TO REPROGRAM MACROPHAGES TO MAKE THE IMMUNE SYSTEM FIGHT THE CANCER AGAIN; DISCOVERED A WAY TO SELECTIVELY REMOVE CERTAIN "PRO-CANCER" IMMUNE CELLS IN OVARIAN TUMORS BY TARGETING A SPECIFIC POCKET ON THE RETINOBLASTOMA (RB) PROTEIN, WHICH HELPS THE IMMUNE SYSTEM FIGHT THE CANCER MORE EFFECTIVELY; CREATED THE FIRST STANDARDIZED SET OF GUIDELINES, TOOLS, AND REFERENCE DATASETS FOR SPATIAL TRANSCRIPTOMICS EXPERIMENTS TO HELP SCIENTISTS COMPARE RESULTS ACROSS LABS AND MEASURE THE QUALITY AND RELIABILITY; UNCOVERED THE RULES THAT GUIDE IMMUNE CELL SIGNALING AND USED THIS KNOWLEDGE TO PROVIDE A WEB RESOURCE TO FACILITATE PROTEIN DESIGN EFFORTS, WHICH CAN BE USED TO DEVELOP NEW IMMUNE-BASED THERAPIES.EVERY DOLLAR DONATED BRINGS US CLOSER TO A CURE FOR THIS DEVASTATING DISEASE. FOR MORE INFORMATION OR TO JOIN US IN OUR FIGHT, PLEASE VISIT OCRA'S WEBSITE AT WWW.OCRAHOPE.ORG. 3162885 0 0 IN 2025, OVARIAN CANCER RESEARCH ALLIANCE (OCRA) PROVIDED COMPREHENSIVE EDUCATION, SUPPORT, AND NAVIGATION SERVICES TO THOUSANDS OF INDIVIDUALS AFFECTED BY OVARIAN AND GYNECOLOGIC CANCERS. OCRA'S PATIENT SUPPORT TEAM RESPONDED TO 4,237 PATIENT AND CAREGIVER CONTACTS THROUGH OUR PATIENT SUPPORT LINE, A 68% INCREASE FROM 2024, PROVIDING EMOTIONAL SUPPORT, INFORMATION, CLINICAL TRIAL GUIDANCE, PEER MENTORING, AND CARE NAVIGATION. OCRA'S WOMAN TO WOMAN PEER MENTOR PROGRAM CONTINUED TO CONNECT NEWLY DIAGNOSED PATIENTS WITH TRAINED SURVIVOR MENTORS THROUGH 19 ACTIVE SITES NATIONWIDE AND A NATIONAL VIRTUAL MATCHING PROGRAM. SINCE ITS LAUNCH, THE PROGRAM HAS FACILITATED MORE THAN 2,800 MENTOR MATCHES. IN 2025, THE NATIONAL TEAM COMPLETED 103 MATCHES AND SUPPORTED 167 MENTORS. OCRA ALSO PROVIDED INDIVIDUALIZED COUNSELING THROUGH ITS STEPS 1:1 COUNSELING PROGRAM AND FACILITATED ONGOING SUPPORT THROUGH STAYING CONNECTED, WHICH ENGAGED 3,530 PARTICIPANTS IN VIRTUAL SUPPORT AND EXPRESSIVE ARTS PROGRAM DURING THE YEAR. TO ADDRESS THE EDUCATIONAL NEEDS OF PATIENTS AND CAREGIVERS, OCRA DELIVERED ITS INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE, WEBINARS, WORKSHOPS, ROUNDTABLES, AND MONTHLY EDUCATIONAL PROGRAMS FOCUSED ON DIAGNOSIS, TREATMENT ADVANCES, SURVIVORSHIP, BIOMARKER TESTING, AND CLINICAL TRIALS. OFFERED FREE OF CHARGE FOR THE FIRST TIME, OCRA'S INTERNATIONAL GYNECOLOGIC CANCER CONFERENCE EXPANDED ITS REACH TO MORE THAN 2,100 PARTICIPANTS WORLDWIDE. NEARLY 300 INDIVIDUALS PARTICIPATED IN OCRA'S EDUCATIONAL WORKSHOPS, INCLUDING OVARIAN CANCER 101, ENDOMETRIAL/UTERINE CANCER 101, AND SURVIVORSHIP SERIES, WHILE NATIONAL WEBINARS REACHED ALMOST 900 PARTICIPANTS. OCRA'S NEW STAYING CURRENT EDUCATIONAL SERIES PROVIDED DISEASE-SPECIFIC UPDATES AND CLINICAL TRIAL INFORMATION TO MORE THAN 200 PARTICIPANTS. COLLECTIVELY, OCRA'S EDUCATIONAL PROGRAMS REACHED MORE THAN 4,000 PARTICIPANTS IN 2025, PROVIDING TIMELY, EVIDENCE-BASED INFORMATION TO HELP PATIENTS AND CAREGIVERS MAKE INFORMED DECISIONS THROUGHOUT THEIR CANCER JOURNEY.IN ADDITION TO ITS SUPPORT AND EDUCATION PROGRAMS, OCRA OFFERS FREE GENETIC TESTING TO QUALIFIED HIGH-RISK INDIVIDUALS AND FACILITATES ACCESSS TO CERTIFIED GENETIC COUNSELORS. SINCE THE PROGRAM'S INCEPTION, OCRA HAS HELPED MORE THAN 3,000 INDIVIDUALS BETTER UNDERSTAND THEIR INHERITED RISK FOR OVARIAN AND OTHER GYNECOLOGIC CANCERS, EMPOWERING THEM AND THEIR FAMILIES TO MAKE INFORMED HEALTHCARE DECISIONS. ADDITIONALLY, OCRA'S CLINICAL TRIAL NAVIGATOR CONTINUED TO EXPAND ACCESS TO CLINICAL TRIAL INFORMATION, WITH 1,540 COMPLETED QUESTIONNAIRES AND MORE THAN 11,700 WEBSITE VISITS IN 2025.OCRA IS ALSO COMMITTED TO DEVELOPING THE NEXT GENERATION OF HEALTHCARE PROFESSIONALS DEDICATED TO IMPROVING OUTCOMES FOR INDIVIDUALS DIAGNOSED WITH GYNECOLOGIC CANCERS. THROUGH OCRA'S ONCOLOGY SOCIAL WORK FIELD PLACEMENT PROGRAM, MASTER OF SOCIAL WORK CANDIDATES RECEIVE SPECIALIZED TRAINING AND SUPERVISION FROM LICENSED CLINICAL SOCIAL WORKERS, GAINING EXPERIENCE ADDRESSING THE UNIQUE PSYCHOLOGICAL, EMOTIONAL, AND PRACTICAL NEEDS OF PATIENTS AND CAREGIVERS AFFECTED BY GYNECOLOGIC CANCERS.OCRA'S SURVIVORS TEACHING STUDENTS (STS) PROGRAM TRAINS OVARIAN CANCER SURVIVORS AND CAREGIVERS TO CONDUCT PRESENTATIONS IN MEDICAL EDUCATION PROGRAMS TO EDUCATE FUTURE HEALTHCARE PROVIDERS ABOUT OVARIAN CANCER. SURVIVORS SHARE THEIR STORIES OF DIAGNOSIS, TREATMENT AND BEYOND, ALONG WITH FACTS ABOUT THE DISEASE. IN 2025, MORE THAN 930 SURVIVOR VOLUNTEERS DELIVERED MORE THAN 400 PRESENTATIONS IN THE US, UK, AND AUSTRALIA REACHING OVER 10,627 MEDICAL, NURSING, AND PHYSICIAN'S ASSISTANT STUDENTS. THESE PRESENTATIONS ENSURE THE NEXT GENERATION OF HEALTH CARE PROVIDERS UNDERSTAND BASIC FACTS ABOUT THE DISEASE, ARE AWARE OF RISK FACTORS, AND CAN IDENTIFY THE SIGNS AND SYMPTOMS OF OVARIAN CANCER, HELPING ENSURE A TIMELY DIAGNOSIS.THROUGH THESE PROGRAMS, OCRA EMPOWERS PATIENTS AND CAREGIVERS WITH TRUSTED INFORMATION, EMOTIONAL SUPPORT, AND CONNECTIONS TO RESOURCES THAT IMPROVE QUALITY OF LIFE AND INFORMED DECISION-MAKING FROM DIAGNOSIS THROUGH SURVIVORSHIP AND BEYOND. 595806 0 0 OVARIAN CANCER RESEARCH ALLIANCE IS A POWERFUL VOICE ON CAPITOL HILL, IN STATEHOUSES AROUND THE COUNTRY AND WITH FEDERAL AGENCIES FOR EVERYONE TOUCHED BY GYNECOLOGIC CANCER. IN 2025, OCRA ESTABLISHED ITS CENTER FOR PUBLIC POLICY TO EXPAND POLICY EDUCATION, LEGISLATIVE TRACKING, AND ADVOCACY ENGAGEMENT OPPORTUNITIES FOR PATIENTS, CAREGIVERS, AND SUPPORTERS NATIONWIDE. OCRA TRAINED AND MOBILIZED MORE THAN 160 ADVOCATES AND SUPPORTERS TO ENGAGE IN THE POLICYMAKING PROCESS. NEARLY 120 ADVOCATES FROM 35 STATES AND THE DISTRICT OF COLUMBIA PARTICIPATED IN OCRA'S ADVOCACY DAY, CONDUCTING MORE THAN 135 MEETINGS WITH CONGRESSIONAL OFFICES. THROUGH 12 GRASSROOTS ACTION ALERTS, ADVOCATES GENERATED MORE THAN 21,000 MESSAGES TO POLICYMAKERS, AND MORE THAN 6,000 NEW ADVOCATES JOINED OCRA'S ADVOCACY NETWORK. OCRA'S ADVOCACY CONTRIBUTED TO PRESERVING FEDERAL FUNDING FOR OVARIAN CANCER RESEARCH AND EDUCATION PROGRAMS, SUPPORTED ENACTMENT OF STATE BIOMARKER ACCESS LAWS, SECURED BIPARTISAN CONGRESSIONAL SUPPORT FOR INCREASED OVARIAN CANCER RESEARCH FUNDING, AND HELPED OBTAIN MORE THAN 120 PROCLAMATIONS AND RESOLUTIONS RECOGNIZING OVARIAN CANCER AWARENESS MONTH. 14206183 1 1 0 1 0 0 0 0 0 0 1 0 0 0 1 1 0 1 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 80 0 29 1 0 0 0 0 0 0 0 0 0 0 0 0 X 18 18 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA FL GA HI IL KS KY MA MD MI MN MS ND NH NJ NM NY OR PA RI SC TN VA WI WV X X X AUDRA L MORAN 2122681002 45 ROCKEFELLER PLAZA 20TH FLOOR NEW YORK NY 101113193 JOHN ORRICO CHAIR 3.00 0.00 X X 0 0 0 MATTHEW NEAL MILLER VICE PRESIDENT 2.00 0.00 X X 0 0 0 MARK TESSAR TREASURER 2.00 0.00 X X 0 0 0 ROBIN S COHEN SECRETARY 2.00 0.10 X X 0 0 0 DEBRA BIRNBAUM DIRECTOR 1.00 0.00 X 0 0 0 JEANNETTE CHANG DIRECTOR 1.00 0.00 X 0 0 0 CARMEL J COHEN MD DIRECTOR THRU AUG 2025 1.00 0.00 X 0 0 0 ANDREW FEUERSTEIN ESQ DIRECTOR 1.00 0.00 X 0 0 0 CAROL J HAMILTON DIRECTOR 1.00 0.00 X 0 0 0 JOHN W HANSBURY ESQ DIRECTOR 1.00 0.10 X 0 0 0 CAROLINE HIRSCH DIRECTOR 1.00 0.00 X 0 0 0 VERONICA JORDAN DIRECTOR THRU SEPT 2025 1.00 0.00 X 0 0 0 THOMAS C LIEBMAN DIRECTOR 1.00 0.00 X 0 0 0 DANA L MARK ESQ DIRECTOR 1.00 0.00 X 0 0 0 CHRIS NEWCOMB DIRECTOR THRU DEC 2025 1.00 0.00 X 0 0 0 MELISSA RIVKIN DIRECTOR 1.00 0.00 X 0 0 0 LISA SCHREIBER DIRECTOR 1.00 0.00 X 0 0 0 LAURA SHAWVER DIRECTOR 1.00 0.00 X 0 0 0 MEI-LI DA SILVA VINT ESQ DIRECTOR 1.00 0.00 X 0 0 0 ELLE SIMONE SCOTT DIRECTOR 1.00 0.00 X 0 0 0 CHRISTOPHER TILBERIS DIRECTOR 1.00 0.00 X 0 0 0 AUDRA L MORAN PRESIDENT & CEO 40.00 0.10 X 333548 0 35207 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 40.00 0.00 X 201949 0 43479 SARAH C DEFEO CHIEF PROGRAM OFFICER 40.00 0.00 X 171149 0 69876 TRACY MOORE VICE PRESIDENT, SUPPORT & EDUCATION 40.00 0.00 X 162573 0 28215 ANNE METTE HERTZ SR DIR TREATMENT ACCESS & SCIENTIFIC EDUCATION 40.00 0.00 X 145000 0 4085 CHAD RAMSEY VICE PRESIDENT, POLICY 40.00 0.00 X 126974 0 26691 JESSICA HUGHSON ANDRADE SENIOR DIRECTOR, STRATEGIC ALLIANCE 40.00 0.00 X 111935 0 24237 NICOLE WARGO VP - PHILANTHROPIC PARTNER 40.00 0.00 X 109257 0 64705 BIBI ALI FORMER CHIEF FINANCIAL OFFICER 0.00 0.00 X 157000 0 0 1519385 0 296495 13 1 1 0 CIRRO BIO INC 225 SOUTH KING STREET SUITE 800 SEATTLE WA 98104 DATA SUPPORT SERVICES 450000 COSGROVE ACCOUNTING 11161 EAST STATE ROAD 70 SUITE 110 LAKEWOOD RANCH FL 34202 ACCOUNTING SERVICES 233127 COLOR HEALTH 831 MITTEN ROAD SUITE 100 BURLINGAME CA 94010 HEREDITARY TESTING 225489 ADC STRATEGIC COMMUNICATIONS 14 KNOB HILL PUTNAM VALLEY NY 10579 MARKETING & COMMUNICATION SERVICES 220766 AMPLIFI 600 RYERSON ROAD SUITE G LINCOLN PARK NJ 07035 MAILING SERVICES 190045 9 458850 17396750 1141580 17855600 1068907 1068907 6341544 5655899 685645 685645 685645 0 458850 112442 -112442 -112442 INSURANCE PROCEEDS 900099 35000 35000 OTHER INCOME 900099 126 126 35126 19532836 0 0 1677236 7888202 7888202 793150 793150 855208 532680 61843 260685 157000 157000 2067817 1418885 64833 584099 54256 29791 5657 18808 391462 249689 38245 103528 215958 136655 20065 59238 124939 42766 76648 5525 304507 304507 9000 9000 87365 87365 1501720 1207117 213272 81331 476124 396611 1441 78072 805711 297041 81578 427092 895459 605873 44594 244992 68238 43180 6340 18718 183739 167510 1433 14796 150636 113394 691 36551 30000 18984 2787 8229 41968 26557 3899 11512 GENETIC TESTING 225489 225489 REPAIRS AND MAINTENANCE 4366 4366 EMPLOYEE EVENTS AND REC 4296 2693 1603 OTHER OPERATING EXPENSE 1459 916 543 17338069 14206183 1177107 1954779 2107359 2710809 1049345 2711451 1212071 434380 69269 149863 313290 263290 80000 50000 33033627 36071656 518932 423770 38070603 42551929 361274 264987 14132020 14759507 0 100000 421488 374810 14914782 15499304 X 10207440 10569811 12948381 16482814 23155821 27052625 38070603 42551929 X 2194767 1439645 262392 X 0 1 X 1 0 X 11263534 15386443 11556311 8538194 17855600 64600082 11263534 15386443 11556311 8538194 17855600 64600082 11342652 53257430 542131 710226 1095100 992906 1068907 4409270 35126 35126 69044478 1334959 0.77130 0.75530 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 5498 11461 16959 15278966 15295925 914796 228699 0 0 723133 837638 751838 914796 3227405 4841108 0 0 22395 16959 39354 180783 209410 187960 228699 806852 1210278 0 0 7500 5498 12998 115471 115471 0 197819 147819 50000 50000 LEASE LIABILITY 374810 374810 X 21581159 1439645 583601 112442 2135688 19445471 87365 87365 19532836 17684355 583601 112442 696043 16988312 87365 262392 349757 17338069 PART X, LINE 2: OCRA RECOGNIZES THE EFFECT OF INCOME TAX POSITIONS ONLY IF THOSE POSITIONS ARE MORE LIKELY THAN NOT TO BE SUSTAINED. MANAGEMENT HAS DETERMINED THAT OCRA HAD NO UNCERTAIN TAX POSITIONS THAT WOULD REQUIRE FINANCIAL STATEMENT RECOGNITION OR DISCLOSURE. OCRA IS NO LONGER SUBJECT TO EXAMINATIONS BY THE APPLICABLE TAXING JURISDICTIONS FOR YEARS PRIOR TO DECEMBER 31, 2022. PART XI, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EVENT EXPENSES REPORTED ON PART VIII 112,442. PART XII, LINE 2D - OTHER ADJUSTMENTS: FUNDRAISING EVENT EXPENSES REPORTED ON PART VIII 112,442. PART XII, LINE 4B - OTHER ADJUSTMENTS: GRANT REFUNDS 262,392. 1 NORTH AMERICA 0 0 GRANTMAKING 793150 0 0 0 0 0 0 793150 0 793150 NORTH AMERICA RESEARCH 793150 WIRE 0 1 0 0 0 0 0 0 0 PART I, LINE 2: OCRA MONITORS THE USE OF GRANT FUNDS BY REQUIRING ALL GRANTEES TO SUBMIT YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS DETAILING THE USE OF FUNDS AND PROGRAM OUTCOMES. THESE REPORTS ARE REVIEWED BY OCRA TO CONFIRM COMPLIANCE WITH THE STATED CHARITABLE OBJECTIVES. PART I, LINE 3: THE ORGANIZATION USED THE ACCRUAL METHOD OF ACCOUNTING TO ACCOUNT FOR EXPENDITURES. SUMMERUN 332429 332429 100874 OVARIAN CYCLE & FITNESS 126421 126421 11568 458850 458850 112442 112442 -112442 1 ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ONE GUSTAVE L LEVY PLACE NEW YORK NY 10029 136171197 501(C)(3) 1948941 0 RESEARCH THE UNIVERSITY OF NEW MEXICO 1700 LOMAS BOULEVARD NORTHEAST ALBUQUERQUE NM 87106 856000642 STATE OF NM 900000 0 RESEARCH CORNELL UNIVERSITY WILLARD STRAIGHT HALL MAILBOX 86 ITHACA NY 14853 150532082 501(C)(3) 900000 0 RESEARCH ROSELL PARK CANCER INSTITUTE ELM AND CARLTON STREETS BUFFALO NY 14263 161391608 501(C)(3) 899997 0 RESEARCH MEMORIAL SLOAN KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131924236 501(C)(3) 650000 0 RESEARCH MASSACHUSETTS GENERAL HOSPITAL 399 REVOLUTION DRIVE NO 645 SOMERVILLE MA 02145 042697983 501(C)(3) 450000 0 RESEARCH SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE 10901 NORTH TORREY PINES ROAD LA JOLLA CA 92037 510197108 501(C)(3) 450000 0 RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BOULEVARD WINSTONSALEM NC 27157 223849199 501(C)(3) 450000 0 RESEARCH UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 104 AIRPORT DRIVE CB1270 CHAPEL HILL NC 27599 566001393 STATE OF NC 271901 0 RESEARCH EMORY UNIVERSITY 1599 CLIFTON ROAD THIRD FLOOR 3101 ATLANTA GA 30322 580566256 501(C)(3) 194950 0 RESEARCH DANA-FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BP418 BOSTON MA 02215 042263040 501(C)(3) 100000 0 RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVENUE NORTH SEATTLE WA 98109 911935159 501(C)(3) 100000 0 RESEARCH THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY 3601 SPRUCE STRET PHILADELPHIA PA 19104 236434390 501(C)(3) 100000 0 RESEARCH UNIVERSITY OF CALIFORNIA IRVINE 228 ALDRICH HALL IRVINE CA 92697 952226406 STATE OF CA 100000 0 RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 1855 FOLSOM STREET SUITE 425 SAN FRANCISCO CA 94103 946036493 STATE OF CA 100000 0 RESEARCH UNIVERSITY OF WASHINGTON 7425 FORSYTH BOULEVARD MSC1299-414-355 SAINT LOUIS MO 63105 430653611 501(C)(3) 100000 0 RESEARCH MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION 204 CRAFT AVENUE PITTSBURGH PA 15213 251462312 501(C)(3) 97413 0 RESEARCH STANFORD UNIVERSITY 485 BROADWAY MAIL CODE 8838 REDWOOD CITY CA 94063 941156365 501(C)(3) 75000 0 RESEARCH 18 0 PART I, LINE 2: OCRA MONITORS THE USE OF GRANT FUNDS BY REQUIRING ALL GRANTEES TO SUBMIT YEARLY FINANCIAL AND NARRATIVE PROGRESS REPORTS DETAILING THE USE OF FUNDS AND PROGRAM OUTCOMES. THESE REPORTS ARE REVIEWED BY OCRA TO CONFIRM COMPLIANCE WITH THE STATED CHARITABLE OBJECTIVES. X X X 1 0 0 0 0 0 0 0 0 AUDRA L MORAN PRESIDENT & CEO 333548 0 0 0 0 0 13342 0 21865 0 368755 0 0 0 JONATHAN ZEIDMAN CHIEF DEVELOPMENT OFFICER 201949 0 0 0 0 0 0 0 43479 0 245428 0 0 0 SARAH C DEFEO CHIEF PROGRAM OFFICER 171149 0 0 0 0 0 7839 0 62037 0 241025 0 0 0 TRACY MOORE VICE PRESIDENT, SUPPORT & EDUCATION 162573 0 0 0 0 0 6503 0 21712 0 190788 0 0 0 NICOLE WARGO VP - PHILANTHROPIC PARTNER 109257 0 0 0 0 0 5938 0 58767 0 173962 0 0 0 BIBI ALI FORMER CHIEF FINANCIAL OFFICER 0 0 0 0 157000 0 0 0 0 0 157000 0 0 0 CHAD RAMSEY VICE PRESIDENT, POLICY 126974 0 0 0 0 0 5079 0 21612 0 153665 0 0 0 PART I, LINE 4A OCRA MADE PAYMENTS TO THE FORMER CHIEF FINANCIAL OFFICER IN THE AMOUNT OF $157,000 IN 2025. THE AMOUNTS WERE TREATED AS TAXABLE COMPENSATION TO THE RECIPIENT AND REPORTED IN PART II, COLUMN (B)(III). X 21 1141580 SALES PRICE 0 0 1 0 PART I, COLUMN (B): THE ORGANIZATION IS REPORTING THE NUMBER OF CONTRIBUTORS IN PART I, COLUMN (B) OF SCHEDULE M. FORM 990, PART I, ITEM C DBA: OVARIAN CANCER RESEARCH ALLIANCE DBA: THE EDMEE FIRTH FUND FOR RESEARCH ON OVARIAN CANCER DBA: THE EDMEE FIRTH FUND FOR RESEARCH IN OVARIAN CANCER FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS PROVIDED TO THE BOARD OF DIRECTORS, AUDIT COMMITTEE, TREASURER, AND THE CEO, AND IS REVIEWED WITH THE EXTERNAL CPA PRIOR TO ITS FILING WITH THE IRS. FORM 990, PART VI, SECTION B, LINE 12C OCRA'S CONFLICT OF INTEREST POLICY (THE "POLICY") APPLIES TO DIRECTORS, OFFICERS AND OTHER EMPLOYEES OR OTHER PERSONS IN A POSITION TO INFLUENCE POLICY OR EXPENDITURES ("KEY PERSONS") WHO ARE ANNUALLY PROVIDED A COPY OF THE POLICY. THE POLICY INCLUDES A REPORTING FORM FOR EXISTING OR POTENTIAL CONFLICTS, AND EACH KEY PERSON IS REQUIRED TO COMPLETE ANNUALLY THE REPORTING FORM. IN CONNECTION WITH ANY PROPOSED TRANSACTION OR ARRANGEMENT BETWEEN OCRA AND ANY SUCH KEY PERSON OR RELATED PERSONS OR ENTITIES THAT RAISES AN ACTUAL OR POTENTIAL CONFLICT OF INTEREST, THE KEY PERSON MUST DISCLOSE THE EXISTENCE AND NATURE OF HIS OR HER RELATIONSHIP AND FINANCIAL INTEREST TO THE PRESIDENT OR THE CHAIR OR CO-CHAIR OF THE BOARD OF DIRECTORS OR THE CHAIR OF ANY AUTHORIZED COMMITTEE. THE POLICY PROVIDES FOR CONSIDERATION OF ANY SUCH TRANSACTION OR ARRANGEMENT BY BOARD OR COMMITTEE MEMBERS BY FOLLOWING CERTAIN MEETING, DISCUSSION, VOTING AND DOCUMENTATION PROCEDURES. OTHER THAN TO PROVIDE INFORMATION OR RESPOND TO QUESTIONS, THE KEY PERSON IS EXCLUDED FROM THE DISCUSSION AND THE DECISION OF WHETHER A CONFLICT OF INTEREST EXISTS. FORM 990, PART VI, SECTION B, LINE 15 OCRA HAS A COMPENSATION COMMITTEE WHICH MEETS ANNUALLY TO REVIEW THE COMPENSATION OF THE CEO. THE COMPENSATION COMMITTEE DETERMINES THE CEO'S COMPENSATION BY UTILIZING DATA FROM COMPARABLY-SIZED ORGANIZATIONS (OBTAINED FORM 990 FILINGS). THE COMPENSATION DECISION IS DOCUMENTED IN THE RECORDS OF THE ORGANIZATION. SALARY INCREASES FOR KEY EMPLOYEES ARE RECOMMENDED BY THE CEO TO THE COMPENSATION COMMITTEE AFTER AN ANNUAL EVALUATION IS COMPLETED. THE COMPENSATION DECISION IS DOCUMENTED IN THE RECORDS OF THE ORGANIZATION. FORM 990, PART VI, SECTION C, LINE 19 FINANCIAL STATEMENTS ARE AVAILABLE ON OCRA'S WEBSITE. ALL OTHER DOCUMENTS ARE AVAILABLE UPON REQUEST. FORM 990, PART XI, LINE 9: GRANT REFUNDS 262,392. OVARIAN CANCER NATIONAL ALLIANCE 1101 14TH STREET NW SUITE 850 WASHINGTON DC 20005 311581756 EDUCATION AND ADVOCACY DC 501(C)(3) LINE 10 THE OVARIAN CANCER RESEARCH FUND INC 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0